Risk-adapted Treatment Strategy For COVID-19 Patients

Abstract

Background: There are no clear expert consensus or guidelines on how to treat 2019 coronavirus disease . The objective of this study is to investigate the short-term effect of risk-adapted treatment strategy on patients with COVID-19. Methods: We collected the medical records of 55 COVID-19 patients for analysis. We divided these patients into mild, moderate and severe groups, and risk-adapted treatment approaches were given according to the illness severity. Results: Twelve patients were in mild group and 22 were in moderate group (non-severe group, n = 34), and 21 patients were in severe group. At the end of the first two weeks after admission, clinical manifestations had completely despeared in 31(91.2%)patients in non-severe group, and 18(85.7%) patients in severe group (p = 0.85). Both groups had a satisfied chest CT imaging recovery, which includes 22(64.7%) patients in non-severe group and 12(57.1%) patients in severe group recovered at least 50% of the whole leisions in the first week, and 28(82.4%) and 16(76.2%) recovered at least 75% in the second week, respectively. There were no significant differences in SARS-CoV-2 nucleic acid negativity (p = 0.92). There were also no significant differences in the levels of SARS-CoV-2-IgM and IgG antibody production between the two groups (p = 0.13, 0.62). There were 45 cases were discharged from the hospital, and no patients died at the time of this clinical analysis. Conclusions: Risk-adapted treatment strategy was associated with significant clinical manifestations alleviation and clinical imaging recovery. In severe COVID-19 patients, early and short-term use of lowdose methylprednisolone was beneficial and did not delay SARS-CoV-2 nucleic acid clearance and influence IgG antibody production.

A primer on viral‐associated olfactory loss in the era of COVID‐19

“…35,36 However, more recent reports and expert recommendations have suggested judicious use of short courses of systemic corticosteroids may be beneficial in those with severe lung injury. 37,38 In our opinion, acute smell loss would not be an appropriate indication given lack of proven benefits and possible risks. Recommendations are less clear for the patient with persistent smell loss who has definitely recovered from COVID-19.…”

COVID-19 Therapeutics Outcome: Systematic Review and Data Analysis

“…A consensus was reached for those studies tobe included (n = 69) without the need for a third reviewer. As seenin Figure 1, the previous systematic review produced 39 of thesearticles and the current study produced 30 articles (referencesfrom 12-80).…”

Prognostic Impact of Coagulopathy in Patients with COVID-19: a Meta-analysis of 35 Studies and 6427 Patients

“…Table 1 summarizes the most relevant characteristics of the selected studies. Sixteen studies were peer-reviewed [5,6,[12][13][14][15][16][17][18][19][20][21][22][23][24][25] , nineteen were non-peer-reviewed [26][27][28][29][30][31][32][33][34][35][36][37][38][39][40][41][42][43][44] . Not surprisingly, quality assessment revealed a non-high study quality (Supplemental Table 1).…”